ViaCyte to Present at Upcoming Scientific Meetings on Diabetes Research
SAN DIEGO, Sept. 7, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held, leading regenerative medicine company, today announced upcoming scientific presentations. ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes. ViaCyte's product candidates have the potential to provide a functional cure for patients with type 1 diabetes as well as an important therapy for patients with type 2 diabetes who depend on insulin to help control their disease.
Details of the presentations are as follows:
| Event: |
Baylor College of Medicine MSTP 40th Anniversary Celebration & Scientific Symposium |
| Speaker: |
Howard Foyt, MD, PhD, Vice President, Clinical Development and Chief Medical Officer of ViaCyte |
| Date/Time: |
September 15, 9:30 am CT |
| Location: |
Houston, Texas |
| Event: |
Canadian Transplant Society and Cell Transplant & Regenerative Medicine Society Joint Scientific Meeting |
| Speaker: |
Alan Agulnick, PhD, Director, Cell Engineering |
| Date/Time: |
September 28, 7:00 am AT |
| Location: |
Halifax, Nova Scotia, Canada |
| Event: |
Mayo Clinic Regenerative Diabetes Program: International Conference on Islet Regeneration and Replacement |
| Speaker: |
Dr. Foyt |
| Date/Time: |
September 30, 10:15 am CT |
| Location: |
Rochester, Minnesota |
| Event: |
43rd Annual Conference of the International Society for Pediatric and Adolescent Diabetes |
| Speaker: |
Dr. Foyt |
| Date/Time: |
October 18, 4:15 pm DST |
| Location: |
Innsbruck, Austria |
For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
About ViaCyte
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in durable and retrievable cell delivery devices. Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels. ViaCyte has two products in clinical development. The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap™ (also known as VC-01) product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin. ViaCyte is headquartered in San Diego, California. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte on Twitter and Facebook.
SOURCE ViaCyte, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article